Research Idea
Research content for general circulation. Not individualized advice.Ā Methodology & Disclosures
Multiple fresh catalysts: Q2 2026 revenue of $796M and adjusted EBITDA of $206M beat estimates, full-year 2026 guidance was raised again, July debt repricing lowers interest costs, and recent FDA approvals add product momentum. Stock is up about 10.5% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ā¢ Margin Expansion ā¢ Elevated Leverage ā¢ Negative Cash Flow AMRX's improving margins and earnings are offset by heavy leverage, declining cash, and negative quarterly free cash flow, warranting caution despite better profitability.
Price Behavior
Key Price Behavior Insights: ā¢ Strong rebound ā¢ Above average ā¢ Key breakout Support Level: $18.00ā$18.06 Resistance Level: $18.71, then $18.85ā$19.10 AMRX is showing bullish last-month momentum above $18.00 support, but needs a break above $19.10 to confirm further upside.
Sentiment & News
Key News Insights: ā¢ Sharp Rebound ā¢ Valuation Concerns ā¢ Defensive Appeal AMRX's sharp rebound highlights defensive appeal, but overvaluation and weak earnings revisions warrant caution.
AI Summary
AMRX is evolving into a higher-growth specialty and biosimilars platform, but with much of that upside already reflected in the stock, investors should require evidence that lanreotide, Kashiv, and margin gains convert into sustained free cash flow to offset heavy leverage and interest costs.
Description
Amneal Pharmaceuticals is a manufacturer and distributor of generic and specialty medicines, operating three reporting segments: Generics, Specialty and AvKARE. Its Generics business produces a broad range of dosage forms while the Specialty unit markets branded therapies across several therapeutic areas; AvKARE supplies pharmaceuticals, medical and surgical products, and packaging services primarily to government and institutional customers. The company sells through wholesalers, hospitals and pharmacies, and maintains operations in the United States, India, Ireland and other international markets; it is headquartered in Bridgewater, New Jersey and was founded in 2002.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 3 | Aug 10 | AMRX | Amneal Pharmaceuticals, Inc. | Multiple fresh catalysts: Q2 2026 revenue of $796M and adjusted EBITDA of $206M beat estimates, full-year 2026 guidance was raised again, July debt repricing lowers interest costs, and recent FDA approvals add product momentum. Stock is up about 10.5% over 21 trading days. | Closed | -5.1% |
| Jun 9 | Jun 16 | AMRX | Amneal Pharmaceuticals, Inc. | Positive catalyst stack with FDA approval of romidepsin injection solution including 180 days of exclusivity, solid Q1 2026 revenue/adjusted EBITDA, reaffirmed higher full-year guidance, and a 14% 21-day stock uptrend with recent breakout strength. | Closed | +10.6% |